Hanmi Science commenced development of oral COVID-19 vaccine

Six visions was announced in post corona era

Promoting the establishment of a research center of ₩300 billion in Pohang

100% annual salary increase is introduced for talents with excellent performance

Hanmi Science, a holding company of Hanmi Pharm Group, is developing 'COVID-19 vaccine for oral use'.

 

In addition, a research center of ₩300 billion is established in Pohang, and an unprecedented personnel system, such as a 100% increase in salary for outstanding talent, is introduced.

 

Hanmi Science unveiled 'The Six Visions for the Post COVID-19 Era' on the 15th

According to the company, the six visions imply 'education','digital','oral','city','green', and 'ocean'.

 

Each item contains ▲Cyber Education ▲Green Bio ▲Oral Bio ▲City Bio ▲Green Bio ▲Marine Bio.

 

It was named 'Cydio Cigma' after the two letters in front of the English letter.

 

The conditions were unprecedented for executives who presented concrete results for the six visions.

 

CEO Jong-Yoon Lim emphasized, "It will destroy the HR system of the existing salary system by raising 100% of annual salary and giving the rank to talented people who perform well in the six vision projects." Specifically, the group plans to establish K-Bio and K-Med Graduate Schools for the 'Cyber Education' project and attract over 5,000 foreign experts.

 

Hanmi Science decided to cooperate with Gyeongsangbuk-do, Pohang-si and Postech to develop new drugs and foster experts in the biotechnology field, human exchange, joint research and technical information exchange, and joint use of research facilities.

 

For the'City Bio' project, a memorandum of understanding was signed on the 15th to build a smart healthcare infrastructure by spending ₩300 billion in Pohang, Gyeongbuk.

 

By 2030, it plans to build a smart healthcare clinical center, a bio open innovation research and development center, and a prototype production facility in 51,846㎡ of the Pohang Free Economic Zone.

 

The'Oral Bio' project is a new oral coronavirus infection (corona19) vaccine research.

 

Applying Hanmi’s Orascovery technology, the company will develop a non-injection vaccine 'Covid MDT'.

 

It is currently preclinical.

 

In addition, Hanmi Science decided to start marine microbiology research (Marine Bio) using Pohang's original 4th generation accelerator.

 

The goal is to uncover the underlying biological mechanisms, such as genomic studies before and after evolution, understanding of inter-microbial ecosystems including viruses, and the origin of human cell function through marine bioresearch.

 

Plant biotechnology will also be applied to expand external appearance.

 

Hanmi Science has promised global joint development and marketing of bio-based venture companies and plant-based bio products called 'green vaccines'.

 

The two companies have decided to establish a joint venture for overseas sales of the world's first plant-based swine fever marker vaccine product commercialized by BioApp.

 

In the near future, a joint venture will be established and product registration will begin in China.

 

In particular, the two companies plan to jointly develop green vaccines against various diseases including COVID-19.

 

Recently, Hanmi signed a technology transfer contract with a professor of Chinese Academy of Agricultural Sciences for a new drug candidate related to metabolic disease, and started developing a new green drug.